MEP16808A - Substituted benzimidazole compounds and their use for the treatment of cancer - Google Patents

Substituted benzimidazole compounds and their use for the treatment of cancer

Info

Publication number: MEP16808A
Authority: ME; Montenegro
Prior art keywords: cancer; treatment; benzimidazole compounds; substituted benzimidazole; compounds
Prior art date: 2001-09-26

Application number

MEP-168/08A

Other languages

Bosnian (bs)

English (en)

Inventor

Francois Clerc

Francois Hamy

Isabelle Depaty

Angouillant-Boniface

Stephanie Deprets

Manfred Carrez

Original Assignee

Aventis Pharma Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-09-26

Filing date

2002-09-26

Publication date

2010-06-10

2002-09-26 Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa

2010-06-10 Publication of MEP16808A publication Critical patent/MEP16808A/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
- C07D235/32—Benzimidazole-2-carbamic acids, unsubstituted or substituted; Esters thereof; Thio-analogues thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

MEP-168/08A 2001-09-26 2002-09-26 Substituted benzimidazole compounds and their use for the treatment of cancer MEP16808A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP01402460A EP1298125A1 (en)	2001-09-26	2001-09-26	Substituted benzimidazole compounds and their use for the treatment of cancer
YUP-214/04A RS50896B (sr)	2001-09-26	2002-09-26	Supstituisana jedinjenja benzimidazola i njihova primena u lečenju raka
PCT/EP2002/011353 WO2003028721A2 (en)	2001-09-26	2002-09-26	Substituted benzimidazole compounds and their use for the treatment of cancer

Publications (1)

Publication Number	Publication Date
MEP16808A true MEP16808A (en)	2010-06-10

Family

ID=8182891

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MEP-168/08A MEP16808A (en)	2001-09-26	2002-09-26	Substituted benzimidazole compounds and their use for the treatment of cancer

Country Status (34)

Country	Link
US (1)	US7041668B2 (xx)
EP (2)	EP1298125A1 (xx)
JP (1)	JP4510450B2 (xx)
KR (1)	KR100891439B1 (xx)
CN (1)	CN100346786C (xx)
AR (1)	AR037096A1 (xx)
AT (1)	ATE386517T1 (xx)
AU (1)	AU2002337151B2 (xx)
BR (1)	BR0212856A (xx)
CA (1)	CA2461622C (xx)
CO (1)	CO5570675A2 (xx)
CY (1)	CY1107953T1 (xx)
DE (1)	DE60225159T2 (xx)
DK (1)	DK1432417T3 (xx)
EA (1)	EA006802B1 (xx)
ES (1)	ES2301682T3 (xx)
GT (1)	GT200200190A (xx)
HR (1)	HRPK20040293B3 (xx)
HU (1)	HUP0401756A3 (xx)
IL (1)	IL161059A0 (xx)
ME (1)	MEP16808A (xx)
MX (1)	MXPA04002042A (xx)
MY (1)	MY135339A (xx)
NO (1)	NO327008B1 (xx)
NZ (1)	NZ531246A (xx)
PA (1)	PA8555501A1 (xx)
PE (1)	PE20030427A1 (xx)
PL (1)	PL369527A1 (xx)
PT (1)	PT1432417E (xx)
RS (1)	RS50896B (xx)
SI (1)	SI1432417T1 (xx)
UY (1)	UY27452A1 (xx)
WO (1)	WO2003028721A2 (xx)
ZA (1)	ZA200401887B (xx)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2011250847B2 (en) *	2003-06-23	2013-06-20	Bhi Limited Partnership	Methods and compositions for treating amyloid-related diseases
US20070010573A1 (en)	2003-06-23	2007-01-11	Xianqi Kong	Methods and compositions for treating amyloid-related diseases
CA2542064A1 (en) *	2003-10-24	2005-05-06	Exelixis, Inc.	Tao kinase modulators and methods of use
DE102004010207A1 (de)	2004-03-02	2005-09-15	Aventis Pharma S.A.	Neue 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate
FR2868421B1 (fr) *	2004-04-01	2008-08-01	Aventis Pharma Sa	Nouveaux benzothiazoles et leur utilisation comme medicaments
EP1598348A1 (en)	2004-05-18	2005-11-23	Aventis Pharma Deutschland GmbH	Novel pyridazinone derivatives as inhibitors of CDK2
CA2592320C (en)	2004-12-22	2015-11-24	Neurochem (International) Limited	Methods and compositions for treating amyloid-related diseases
UA92180C2 (xx) *	2005-09-06	2010-10-11	Смиткляйн Бичам Корпорейшн	Сполуки бензімідазолтіофену[соединения бензимидазолтиофена
FR2891273B1 (fr) *	2005-09-27	2007-11-23	Aventis Pharma Sa	NOUVEAUX DERIVES BENZIMIDAZOLES ET BENZOTHIAZOLES, LEUR PREPARATION ET LEUR UTILISATION PHARMACEUTIQUE NOTAMMENT COMME INHIBITEURS DE CMet
ES2533463T3 (es)	2006-10-12	2015-04-10	Bhi Limited Partnership	Métodos, compuestos, composiciones y vehículos para suministrar ácido 3-amino-1-propanosulfónico
PA8792501A1 (es)	2007-08-09	2009-04-23	Sanofi Aventis	Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.
UA113277C2 (xx) *	2007-10-12	2017-01-10		Комбінація кристалічної форми1 2-((r)-2-метилпіролідин-2-іл)-1н-бензімідазол-4-карбоксаміду та протиракового лікарського засобу
FR2922550B1 (fr)	2007-10-19	2009-11-27	Sanofi Aventis	Nouveaux derives de 6-aryl/heteroalkyloxy benzothiazole et benzimidazole, application comme medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de cmet
FR2941950B1 (fr)	2009-02-06	2011-04-01	Sanofi Aventis	Derives de 6-(6-o-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941952B1 (fr)	2009-02-06	2011-04-01	Sanofi Aventis	Derives de 6-(6-substitue-triazolopyridazine-sulfanyl) 5-fluoro-benzothiazoles et 5-fluoro-benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941951B1 (fr)	2009-02-06	2011-04-01	Sanofi Aventis	Derives de 6-(6-nh-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941949B1 (fr)	2009-02-06	2011-04-01	Sanofi Aventis	Derives de 6-(6-o-cycloalkyl ou 6-nh-cycloalkyl- triazolopyridazine-sulfanyl)benzothiazoles et benzimidazoles preparation, application comme medicaments et utilisation comme inhibiteurs de met.
WO2011091152A1 (en) *	2010-01-22	2011-07-28	Pablo Gastaminza	Inhibitors of hepatitis c virus infection
SMT201800039T1 (it)	2012-12-05	2018-03-08	Alnylam Pharmaceuticals Inc	Composizioni di irna di pcsk9 e metodi di uso delle stesse
AU2016310494B2 (en)	2015-08-25	2022-06-09	Alnylam Pharmaceuticals, Inc.	Methods and compositions for treating a proprotein convertase subtilisin kexin (PCSK9) gene-associated disorder

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2441201C2 (de) *	1974-08-28	1986-08-07	Hoechst Ag, 6230 Frankfurt	Anthelminthisch wirksame 2-Carbalkoxyamino-5(6)-phenyl-sulfonyloxy-benzimidazole und Verfahren zu ihrer Herstellung
DE2541752A1 (de)	1975-09-19	1977-03-24	Hoechst Ag	Anthelminthisch wirksame 2-carbalkoxyamino-5(6)-phenyl-sulfonyloxy- benzimidazole und verfahren zu ihrer herstellung
DE3247615A1 (de) *	1982-12-23	1984-07-05	Hoechst Ag, 6230 Frankfurt	Substituierte phenylsulfonyloxybenzimidazolcarbaminate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
GB9900752D0 (en) *	1999-01-15	1999-03-03	Angiogene Pharm Ltd	Benzimidazole vascular damaging agents
US6693125B2 (en) *	2001-01-24	2004-02-17	Combinatorx Incorporated	Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders

2001
- 2001-09-26 EP EP01402460A patent/EP1298125A1/en not_active Withdrawn
2002
- 2002-09-17 PE PE2002000913A patent/PE20030427A1/es not_active Application Discontinuation
- 2002-09-24 UY UY27452A patent/UY27452A1/es unknown
- 2002-09-25 MY MYPI20023586A patent/MY135339A/en unknown
- 2002-09-25 GT GT200200190A patent/GT200200190A/es unknown
- 2002-09-26 DK DK02772370T patent/DK1432417T3/da active
- 2002-09-26 DE DE60225159T patent/DE60225159T2/de not_active Expired - Lifetime
- 2002-09-26 RS YUP-214/04A patent/RS50896B/sr unknown
- 2002-09-26 AR ARP020103629A patent/AR037096A1/es unknown
- 2002-09-26 PT PT02772370T patent/PT1432417E/pt unknown
- 2002-09-26 CA CA002461622A patent/CA2461622C/en not_active Expired - Fee Related
- 2002-09-26 HR HR20040293A patent/HRPK20040293B3/xx not_active IP Right Cessation
- 2002-09-26 EP EP02772370A patent/EP1432417B1/en not_active Expired - Lifetime
- 2002-09-26 JP JP2003532053A patent/JP4510450B2/ja not_active Expired - Fee Related
- 2002-09-26 BR BR0212856-0A patent/BR0212856A/pt not_active IP Right Cessation
- 2002-09-26 NZ NZ531246A patent/NZ531246A/en not_active IP Right Cessation
- 2002-09-26 ME MEP-168/08A patent/MEP16808A/xx unknown
- 2002-09-26 MX MXPA04002042A patent/MXPA04002042A/es active IP Right Grant
- 2002-09-26 EA EA200400475A patent/EA006802B1/ru not_active IP Right Cessation
- 2002-09-26 AT AT02772370T patent/ATE386517T1/de active
- 2002-09-26 KR KR1020047004365A patent/KR100891439B1/ko not_active Expired - Fee Related
- 2002-09-26 AU AU2002337151A patent/AU2002337151B2/en not_active Ceased
- 2002-09-26 IL IL16105902A patent/IL161059A0/xx unknown
- 2002-09-26 PA PA20028555501A patent/PA8555501A1/es unknown
- 2002-09-26 HU HU0401756A patent/HUP0401756A3/hu unknown
- 2002-09-26 PL PL02369527A patent/PL369527A1/xx not_active Application Discontinuation
- 2002-09-26 SI SI200230686T patent/SI1432417T1/sl unknown
- 2002-09-26 WO PCT/EP2002/011353 patent/WO2003028721A2/en not_active Ceased
- 2002-09-26 ES ES02772370T patent/ES2301682T3/es not_active Expired - Lifetime
- 2002-09-26 CN CNB028187458A patent/CN100346786C/zh not_active Expired - Fee Related
2004
- 2004-03-08 ZA ZA200401887A patent/ZA200401887B/en unknown
- 2004-03-23 NO NO20041214A patent/NO327008B1/no not_active IP Right Cessation
- 2004-03-25 CO CO04028337A patent/CO5570675A2/es not_active Application Discontinuation
- 2004-03-25 US US10/808,889 patent/US7041668B2/en not_active Expired - Fee Related
2008
- 2008-05-20 CY CY20081100526T patent/CY1107953T1/el unknown

Also Published As

Publication number	Publication date
GT200200190A (es)	2003-11-11
NO327008B1 (no)	2009-04-06
UY27452A1 (es)	2003-02-28
HK1068551A1 (en)	2005-04-29
CA2461622A1 (en)	2003-04-10
ATE386517T1 (de)	2008-03-15
CO5570675A2 (es)	2005-10-31
PA8555501A1 (es)	2003-06-30
MXPA04002042A (es)	2004-06-07
CY1107953T1 (el)	2013-09-04
YU21404A (sh)	2006-08-17
CA2461622C (en)	2008-12-02
PT1432417E (pt)	2008-05-23
EA200400475A1 (ru)	2004-08-26
EP1432417B1 (en)	2008-02-20
AR037096A1 (es)	2004-10-20
EP1432417A2 (en)	2004-06-30
AU2002337151B2 (en)	2007-04-26
KR100891439B1 (ko)	2009-04-03
CN100346786C (zh)	2007-11-07
PL369527A1 (en)	2005-05-02
DK1432417T3 (da)	2008-06-16
NO20041214L (no)	2004-06-24
SI1432417T1 (sl)	2008-08-31
RS50896B (sr)	2010-08-31
DE60225159T2 (de)	2009-02-19
HRP20040293A2 (en)	2005-06-30
US7041668B2 (en)	2006-05-09
EA006802B1 (ru)	2006-04-28
HUP0401756A3 (en)	2005-06-28
IL161059A0 (en)	2004-08-31
JP2005504112A (ja)	2005-02-10
CN1558761A (zh)	2004-12-29
WO2003028721A3 (en)	2003-12-11
JP4510450B2 (ja)	2010-07-21
NZ531246A (en)	2006-06-30
DE60225159D1 (de)	2008-04-03
PE20030427A1 (es)	2003-06-20
EP1298125A1 (en)	2003-04-02
KR20040048904A (ko)	2004-06-10
MY135339A (en)	2008-03-31
HRPK20040293B3 (hr)	2007-06-30
WO2003028721A2 (en)	2003-04-10
ZA200401887B (en)	2005-05-31
ES2301682T3 (es)	2008-07-01
BR0212856A (pt)	2004-09-14
US20050014811A1 (en)	2005-01-20
HUP0401756A2 (hu)	2005-01-28

Publication	Publication Date	Title
MEP16808A (en)	2010-06-10	Substituted benzimidazole compounds and their use for the treatment of cancer
ATE300529T1 (de)	2005-08-15	Imidazolderivate als raf-kinase-inhibitoren
BRPI0207961A8 (pt)	2017-09-19	Uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
SE0101387D0 (sv)	2001-04-20	Novel compounds
BRPI0415525A (pt)	2006-12-26	derivados de imidazola e seu uso como agentes farmacêuticos
NO20071875L (no)	2007-06-14	Bicykliske amider som kinaseinhibitorer
DE50310516D1 (de)	2008-10-30	Fredericamycin-derivate
DE60206911D1 (de)	2005-12-01	Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
EA200501849A1 (ru)	2006-06-30	Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
NO20014560L (no)	2001-09-19	Quinasoliner og terapautisk anvendelse derav
EE200300475A (et)	2004-02-16	Türosiini kinaasi inhibiitorid, neid sisaldavad ravimkoostised ja nimetatud ühendid kasutamiseks haiguste ravis
SE0301700D0 (sv)	2003-06-10	Novel compounds
NO20024005D0 (no)	2002-08-22	Pteridinforbindelser for behandling av psoriasis
BRPI0510177B8 (pt)	2021-05-25	composto, composição farmacêutica e uso do mesmo
NO20071585L (no)	2007-04-30	Ny anvendelse av peptidforbindelser for behandling av benkreftsmerte, kjemoterapi- og nucleosidfremkalt smerte
CR7716A (es)	2008-11-25	Uso de inhibidores de la ikb-quinasa para el tratamiento del dolor
GB0121490D0 (en)	2001-10-24	Ciompounds
SE0300098D0 (sv)	2003-01-15	Use of cyclin D1 inhibitors
DE60129829D1 (de)	2007-09-20	Zyklisierte benzamid-neurokinin-antagonisten zur verwendung in therapie
GB0121494D0 (en)	2001-10-24	Compounds
DE60213798D1 (de)	2006-09-21	Carbolinderivate als pdev inhibitoren
DE60010934D1 (de)	2004-06-24	Medikamente geeignet zur Behandlung von proliferativen Erkrankungen
ATE423780T1 (de)	2009-03-15	Makrozyclen zur behandlung von krebserkrankungen
ATE431348T1 (de)	2009-05-15	Thiaepothilone zur behandlung von krebserkrankungen
ECSP034516A (es)	2003-04-25	Compuestos de pirazol utiles como inhibidores de protein quinasa